FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?

Unresectable hepatocellular carcinoma (HCC) is an advanced primary liver malignancy with a poor prognosis. The Food and Drug Administration (FDA) has, to date, approved nivolumab, pembrolizumab, ramucirumab, nivolumab/ipilimumab, atezolizumab/bevacizumab, as well as tremelimumab/durvalumab, as first...

Descripción completa

Detalles Bibliográficos
Autores principales: Psilopatis, Iason, Damaskos, Christos, Garmpi, Anna, Sarantis, Panagiotis, Koustas, Evangelos, Antoniou, Efstathios A., Dimitroulis, Dimitrios, Kouraklis, Gregory, Karamouzis, Michail V., Vrettou, Kleio, Marinos, Georgios, Kontzoglou, Konstantinos, Garmpis, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916803/
https://www.ncbi.nlm.nih.gov/pubmed/36769004
http://dx.doi.org/10.3390/ijms24032685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916803/
https://www.ncbi.nlm.nih.gov/pubmed/36769004
http://dx.doi.org/10.3390/ijms24032685

Ejemplares similares